The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

NCT03463057 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

109

Enrollment

OTHER

Sponsor class

Conditions

NHL
DLBCL

Interventions

DRUG: Atezolizumab

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland